IR@PKUHSC  > 北京大学临床肿瘤学院  > 淋巴肿瘤内科
学科主题临床医学
Homozygous A polymorphism of the complement C1qA(276) correlates with prolonged overall survival in patients with diffuse large B cell lymphoma treated with R-CHOP
Jin, Xuan2; Ding, Huirong3; Ding, Ning1; Fu, Zhiying1; Song, Yuqin1; Zhu, Jun1
关键词Complement Polymorphism Rituximab DLBCL C1qA
刊名JOURNAL OF HEMATOLOGY & ONCOLOGY
2012-08-16
DOI10.1186/1756-8722-5-51
5
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology ; Hematology
研究领域[WOS]Oncology ; Hematology
关键词[WOS]CHRONIC LYMPHOCYTIC-LEUKEMIA ; CHEMOTHERAPY PLUS RITUXIMAB ; C1Q BINDING-SITE ; ELDERLY-PATIENTS ; IN-VIVO ; EFFECTOR MECHANISMS ; ANTIBODY ; ACTIVATION ; EXPRESSION ; INHIBITORS
英文摘要

Background: The precise mechanism of action for rituximab (R) is not fully elucidated. Besides antibody-dependent cellular cytotoxicity (ADCC), complements may also play an important role in the clinical response to rituximab-based therapy in diffuse large B cell lymphoma (DLBCL). The purpose of this study was to explore the relationship between C1qA([276]) polymorphism and the clinical response to standard frontline treatment with R-CHOP in DLBCL patients.

Methods: Genotyping for C1qA([276A/G]) was done in 164 patients with DLBCL. 129 patients treated with R-CHOP as frontline therapy (R >= 4 cycles) were assessable for the efficacy.

Results: Patients with homozygous A were found to have a higher overall response rate than those with heterozygous or homozygous G alleles (97.3% vs. 83.7%, P = 0.068). The complete response rate in patients with homozygous A was statistically higher than that in AG and GG allele carriers (89.2% vs. 51.1%, P = 0.0001). The overall survival of patients with homozygous A was longer than that of the G allele carriers (676 days vs. 497 days, P = 0.023). Multivariate Cox regression analysis showed that C1qA A/A allele was an independent favorable prognostic factor for DLBCL patients treated with R-CHOP as first-line therapy.

Conclusion: These results suggest that C1qA polymorphism may be a biomarker to predict response to R-CHOP as frontline therapy for DLBCL patients.

语种英语
WOS记录号WOS:000309879700001
项目编号30973484
资助机构National Science Foundation Committee of China
引用统计
被引频次:13[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/67061
专题北京大学临床肿瘤学院_淋巴肿瘤内科
北京大学第一临床医学院_肿瘤化疗科
北京大学临床肿瘤学院_中心实验室
作者单位1.Peking Univ, Canc Hosp & Inst, Dept Lymphoma, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100142, Peoples R China
2.Peking Univ, Hosp 1, Dept Internal Med Oncol, Beijing 100034, Peoples R China
3.Peking Univ, Canc Hosp & Inst, Cent Lab, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100142, Peoples R China
推荐引用方式
GB/T 7714
Jin, Xuan,Ding, Huirong,Ding, Ning,et al. Homozygous A polymorphism of the complement C1qA(276) correlates with prolonged overall survival in patients with diffuse large B cell lymphoma treated with R-CHOP[J]. JOURNAL OF HEMATOLOGY & ONCOLOGY,2012,5.
APA Jin, Xuan,Ding, Huirong,Ding, Ning,Fu, Zhiying,Song, Yuqin,&Zhu, Jun.(2012).Homozygous A polymorphism of the complement C1qA(276) correlates with prolonged overall survival in patients with diffuse large B cell lymphoma treated with R-CHOP.JOURNAL OF HEMATOLOGY & ONCOLOGY,5.
MLA Jin, Xuan,et al."Homozygous A polymorphism of the complement C1qA(276) correlates with prolonged overall survival in patients with diffuse large B cell lymphoma treated with R-CHOP".JOURNAL OF HEMATOLOGY & ONCOLOGY 5(2012).
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Jin, Xuan]的文章
[Ding, Huirong]的文章
[Ding, Ning]的文章
百度学术
百度学术中相似的文章
[Jin, Xuan]的文章
[Ding, Huirong]的文章
[Ding, Ning]的文章
必应学术
必应学术中相似的文章
[Jin, Xuan]的文章
[Ding, Huirong]的文章
[Ding, Ning]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。